Compared with subcutaneous or intramuscular routes for vaccination, vaccine delivery via gastrointestinal mucosa has tremendous potential as it is easy to administer and pain free. Robust immune responses can be triggered successfully once vaccine carried antigen reaches the mucosal associated lymphoid sites (e.g., Peyer’s patches). However, the absence of an efficient delivery method has always been an issue for successful oral vaccine development. In our study, inspired by mammalian orthoreovirus (MRV) transport into gut mucosal lymphoid tissue via Microfold cells (M cells), artificial virus-like nanocarriers (AVN), consisting of gold nanocages functionalized with the 1 protein from mammalian reovirus (MRV), were tested as an effective oral vaccine delivery vehicle targeting M cells. AVN was shown to have a significantly higher transport compared to other experimental groups across mouse organoid monolayers containing M cells. These findings suggest that AVN has the potential to be an M cell-specific oral vaccine/drug delivery vehicle.